LANDMARK Trial: a Randomised Controlled Trial of Myval THV
ConditionAortic Valve Stenosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMeril Life Sciences Pvt. Ltd.
About this trial
The primary objective of this study (LANDMARK) is to compare the safety and effectiveness of the Myval THV Series with Contemporary Valves (Sapien THV Series and Evolut THV Series) in patients with severe symptomatic native aortic valve stenosis.
This study will be done in total 768 subjects (384:384, Myval THV Series vs. Contemporary Valves)
The randomisation will be carried out with an allocation ratio of 1:1 between Myval THV Series vs. Contemporary Valves (Sapien THV Series and Evolut THV Series)
Eligibility criteria
Qualifiers
Patient ≥18 years of age.
Patient or their legal representative has provided written informed consent as approved by the Institutional Review Board (IRB)/Institutional Ethics Committee (IEC) of the investigational site to participate in the study.
As per local Heart Team assessment, patient is eligible for TAVI and the patient is suitable for implantation with all three study devices.
Disqualifiers
Patients who are not willing to provide informed consent form, or whose legal heirs object to their participation in the study.
Any condition, which in the Investigator's opinion, would preclude safe participation of patient in the study.
Trial design
Treatments tested in this trial
- Myval THV Series
- Contemporary Valves (Sapien THV Series and Evolut THV Series)
Treatment groups
988 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov